| Poly(butylmethacrylate) and rapamycin coated stent -> Monitor Keywords |
|
|
  Poly(butylmethacrylate) and rapamycin coated stentUSPTO Application #: 20070198081Title: Poly(butylmethacrylate) and rapamycin coated stent Abstract: A drug eluting stent is disclosed. The stent includes a stent base; a basecoat formulation comprising Sirolimus in a polymer coating, wherein the polymer coating contains ethylene-co-vinyl acetate and poly-n-butyl methacrylate; and a topcoat disposed on the basecoat formulation. (end of abstract) Agent: Squire, Sanders & Dempsey LLP - San Francisco, CA, US Inventors: Daniel Castro, Stephen D. Pacetti USPTO Applicaton #: 20070198081 - Class: 623001420 (USPTO) Related Patent Categories: Prosthesis (i.e., Artificial Body Members), Parts Thereof, Or Aids And Accessories Therefor, Arterial Prosthesis (i.e., Blood Vessel), Drug Delivery The Patent Description & Claims data below is from USPTO Patent Application 20070198081. Brief Patent Description - Full Patent Description - Patent Application Claims
CROSS REFERENCE [0001] This application is a continuation of U.S. patent application Ser. No. 11/132,048 filed on May 17, 2005, which is a divisional application of U.S. patent application Ser. No. 10/678,346 filed Oct. 3, 2003 (U.S. Pat. No. 6,953,560), which is a continuation application of U.S. patent application Ser. No. 09/676,049 filed Sep. 28, 2000 (U.S. Pat. No. 6,716,444). This divisional application claims the priority benefit of U.S. patent application Ser. Nos. 11/132,048, 10/678,346 and 09/676,049, and this divisional application hereby incorporates by reference the complete contents of these applications. BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates to implantable medical devices that release a drug. [0004] 2. Description of the Background [0005] Percutaneous transluminal coronary angioplasty (PTCA) is a procedure for treating heart disease. A catheter assembly having a balloon portion is introduced into the cardiovascular system of a patient via the brachial or femoral artery. The catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion. Once in position across the lesion, the balloon is inflated to a predetermined size to radially compress against the atherosclerotic plaque of the lesion to model the arterial lumen. The balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature. [0006] In treating the damaged vasculature tissue, and to deter thrombosis and restenosis, drugs are commonly administered to the treatment site. For example, anticoagulants are commonly used to prevent thrombosis of the coronary lumen. Antiplatelets are administered to reduce the incidence of major adverse cardiac events. Cytostatic agents are presently used in clinical trials to reduce post-angioplasty proliferation of the vascular tissue. [0007] Systemic administration of such drugs in sufficient amounts to supply an efficacious concentration to the local treatment site often produces adverse or toxic side effects for the patient. Accordingly, local delivery is a preferred method of treatment since smaller amounts of medication are administered in comparison to systemic dosages, but the medication is concentrated at a specific treatment site. Local delivery thus produces fewer side effects and achieves more effective results. [0008] A common technique for local delivery of drugs involves coating a stent or graft with a polymeric material which, in turn, is impregnated with a drug or a combination of drugs. Once the stent or graft is implanted within a cardiovascular system lumen, the drug(s) is released from the polymer for the treatment of the local tissues. U.S. Pat. No. 5,605,696 to Eury et al., U.S. Pat. No. 5,464,650 to Berg, et al., and U.S. Pat. No. 5,700,286 to Tartaglia, et al. provide examples illustrating the use of a polymeric coating for the local delivery of a drug or substance. [0009] Stents are scaffoldings, usually cylindrical or tubular in shape, which are inserted into an anatomical passageway and operate to physically hold open and, if desired, to expand the wall of a passageway. Stents are capable of being crimped onto balloon catheters for insertion through small cavities, positioned in a desired location, and then expanded to a larger diameter. Stents can be either balloon expandable or self-expanding. [0010] Grafts are typically placed in a blood vessel to either replace a diseased segment that has been removed, or to form a bypass conduit through a damaged segment of the vessel wall as is the case with an aneurysm, for example. The graft has a tubular portion which spans the site of the damaged tissue and through which the blood flows. The graft has sections at both ends of the tube that are used to secure the graft to the inside of a vessel wall. The graft also has an outer surface, portions of which are in contact with an inner surface of the blood vessel wall, and an inner surface in contact with the blood flowing through the vessel. [0011] FIG. 1 shows an implantable medical device 10, which may be a stent or graft. Device 10 includes a substrate 12 that may be formed of stainless steel, nickel titanium alloy, or another biocompatible metal. Substrate 12 is covered (usually conformally) by a first layer 14. First layer 14 includes polymer containing a drug 16. [0012] An equation describing the drug release rate per unit area of device 10 is as follows: .PHI. .function. ( t ) = D p .times. n = 0 - .times. b n .times. exp ( - .pi. 2 .times. D p .times. t .function. ( 2 .times. n + 1 ) 2 4 .times. T 2 ) .times. ( - .pi. 2 .times. T .function. ( 2 .times. n + 1 ) n ) ( Equation .times. .times. 1 ) [0013] where .PHI.(t)=release rate of drug as a function of time, [0014] D.sub.p=diffusivity of drug 16 in polymer film 14, [0015] .pi.=3.14159, [0016] T=thickness of polymer film 14, [0017] and b.sub.n b n = 2 T .times. .intg. O T .times. C O .times. cos .times. { .pi. .times. .times. x .function. ( 2 .times. n + 1 ) 2 .times. T } .times. d x where Co is the concentration of drug in the polymer at time zero. [0018] Equation 1 assumes that: (1) all resistance to drug release is determined by the diffusivity of drug 16 in polymer 14; (2) the concentration of drug 16 is uniform throughout; (3) drug 16 does not go into the metallic surface 12; and (4) drug 16 is rapidly removed from the surface of polymer 14 as soon as drug 16 is released from polymer 14. [0019] The diffusivity of drug 16 in polymer 14, D.sub.P, in turn is determined by certain properties of drug 16 (e.g., molecular weight, size) and physical properties of the polymer 14 through which drug 16 is diffusing (e.g., pore size, crystallinity, glass transition temperature, polarity or hydrophobicity). [0020] FIG. 2 illustrates the predicted drug release rate curve for a polymer matrix carrying a drug, such as first layer 14, illustrated in FIG. 1. Curve 8 is an exponentially decreasing curve. [0021] A problem associated with the use of a polymeric coating as a matrix for carrying the drug is that the rate at which the drug is released is highly variable, typically exhibiting a very high rate of release after the medical device is implanted in the patient, followed by a significantly lower rate of release. This may be undesirable in many applications, since the initial concentrations may be too high (causing undesirable side effects or even cell death), the later concentrations may be too low to have any therapeutic effect, and the overall residence time of the drug in the target area may be too short to provide the desired therapeutic effect. [0022] For example, for certain antiproliferative drugs, a residence time of thirty minutes may be all that is required to achieve a permanent effect, while others may take up to two weeks. Where nitrous oxide (NO) is used as the antiproliferative drug, a residence time of four to eight weeks is desirable, but even longer durations up to twelve weeks may be beneficial, depending on the patient. [0023] With respect to anti-inflammatory drugs, a long residence time (e.g., several weeks) is desirable, because the anti-inflammatory drug should be delivered until some amount of healing has occurred. Anti-thrombogenic drugs also may require a long residence time, for example, up to five months, since that much time may be required for a stent to become endothelialized. [0024] Thus, there is a need for a mechanism for controlling the release rate of drugs from implantable medical devices to increase the efficacy of local drug delivery in treating patients. SUMMARY OF THE INVENTION Continue reading... Full patent description for Poly(butylmethacrylate) and rapamycin coated stent Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Poly(butylmethacrylate) and rapamycin coated stent patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Poly(butylmethacrylate) and rapamycin coated stent or other areas of interest. ### Previous Patent Application: Coatings including an antioxidant Next Patent Application: Apparatus and method for treating a regurgitant valve Industry Class: Prosthesis (i.e., artificial body members), parts thereof, or aids and accessories therefor ### FreshPatents.com Support Thank you for viewing the Poly(butylmethacrylate) and rapamycin coated stent patent info. IP-related news and info Results in 1.45925 seconds Other interesting Feshpatents.com categories: Software: Finance , AI , Databases , Development , Document , Navigation , Error |
||
